MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

被引：1

作者：

O'Connor, P ^{[1
]}

Fleming, P ^{[1
]}

Gray, T ^{[1
]}

Jacobs, L ^{[1
]}

Miller, C ^{[1
]}

Munschauer, F ^{[1
]}

Kinkel, RP ^{[1
]}

Bolibrush, D ^{[1
]}

Cohen, J ^{[1
]}

Freedman, M ^{[1
]}

Webb, U ^{[1
]}

Rabinowicz, H ^{[1
]}

Metz, LM ^{[1
]}

Patry, D ^{[1
]}

Yeung, M ^{[1
]}

Peters, S ^{[1
]}

Hashimoto, S ^{[1
]}

Morrison, W ^{[1
]}

Oger, J ^{[1
]}

Panitch, H ^{[1
]}

Costello, K ^{[1
]}

Bever, C ^{[1
]}

Stuart, W ^{[1
]}

Court, D ^{[1
]}

Stuart, D ^{[1
]}

Tornatore, C ^{[1
]}

Bartlett, D ^{[1
]}

Richert, J ^{[1
]}

Duquette, P ^{[1
]}

Dubois, R ^{[1
]}

Bernier, G ^{[1
]}

Scott, T ^{[1
]}

Pappert, L ^{[1
]}

Brillman, J ^{[1
]}

Felton, W ^{[1
]}

Anderson, T ^{[1
]}

Astruc, J ^{[1
]}

Rose, J ^{[1
]}

Kline, J ^{[1
]}

Burns, J ^{[1
]}

Murray, T ^{[1
]}

Weldon, P ^{[1
]}

Bhan, V ^{[1
]}

Maxner, CE ^{[1
]}

Wall, M ^{[1
]}

Vining, L ^{[1
]}

Grabowski, T ^{[1
]}

Apatoff, B ^{[1
]}

Orapello, C ^{[1
]}

Friedman, J ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA

来源：

NEUROLOGY | 2002年 / 59卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

引用

页码：998 / 1005

页数：8

共 50 条

[41] THE LONG-TERM RISK OF DEVELOPING CLINICALLY DEFINITE MS, RECURRENT MYELITIS AND MRI-SUPPORTED MS AFTER AN ISOLATED EPISODE OF PARTIAL TRANSVERSE MYELITIS
STEVENS, GHJ
WEINSTOCKGUTTMAN, B
KINKEL, RP
NEUROLOGY, 1995, 45 (04) : A332 - A333
[42] Early MRI predictors of clinical progression over 48 months in patients with clinically isolated syndrome
Uher, T.
Horakova, D.
Kalincik, T.
Bergsland, N.
Tyblova, M.
Ramasamy, D. P.
Seidl, Z.
Vaneckova, M.
Krasensky, J.
Havrdova, E.
Zivadinov, R.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 404 - 405
[43] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
Comi, G.
Martinelli, V.
Rodegher, M.
Moiola, L.
Bajenaru, O.
Carra, A.
Elovaara, I.
Fazekas, F.
Hartung, H. P.
Hillert, J.
King, J.
Komoly, S.
Lubetzki, C.
Montalban, X.
Myhr, K. M.
Ravnborg, M.
Rieckmann, P.
Wynn, D.
Young, C.
Filippi, M.
LANCET, 2009, 374 (9700): : 1503 - 1511
[44] Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria
Lo, C-P
Kao, H-W
Chen, S-Y
Hsueh, C-J
Lin, W-C
Hsu, W-L
Wu, D-K
Liu, G-C
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (10): : 1107 - 1109
[45] Oral Cladribine Delays Time to Conversion to Clinically Definite MS in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study
Leist, Thomas
Comi, Giancarlo
Cree, Bruce
Coyle, Patricia
Freedman, Mark
Hartung, Hans
Vermersch, Patrick
Orejudos, Amelia
Lachenal, Nathalie
Scaramozza, Matthew
NEUROLOGY, 2013, 80
[46] Expression of the quiescence marker, TOB-1, in T-cells of CIS patients at high risk of rapid conversion to clinically definite MS
Basdeo, S.
Kelly, S.
O'Connell, K.
Tubridy, N.
Hutchinson, M.
Fletcher, J.
McGuigan, C.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 361 - 361
[47] Effect of early interferon beta-1a therapy on conversion to clinically definite multiple sclerosis in Iranian patients with a first demyelinating event
Pakdaman, H.
Fallah, A.
Pakdaman, R.
Sahraian, M. A.
Ghafarpour, M.
Gharaeghouzli, K.
JOURNAL OF NEUROLOGY, 2007, 254 : 166 - 166
[48] Effect of early interferon-beta1-a therapy on conversion to clinically definite multiple sclerosis in Iranian patients with a first demyelinating event
Pakdaman, H.
Fallah, A.
Pakdaman, R.
Shirani, A.
Sahraian, M.
MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S210 - S210
[49] Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
Stellmann, Jan-Patrick
Stuerner, Klarissa Hanja
Young, Kim Lea
Siemonsen, Susanne
Friede, Tim
Heesen, Christoph
PLOS ONE, 2015, 10 (02):
[50] Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Leist, Thomas P.
Comi, Giancarlo
Cree, Bruce A. C.
Coyle, Patricia K.
Freedman, Mark S.
Hartung, Hans-Peter
Vermersch, Patrick
Casset-Semanaz, Florence
Scaramozza, Matthew
LANCET NEUROLOGY, 2014, 13 (03): : 257 - 267

← 1 2 3 4 5 →